These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15479840)

  • 1. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.
    King NM; Prabu-Jeyabalan M; Nalivaika EA; Wigerinck P; de Béthune MP; Schiffer CA
    J Virol; 2004 Nov; 78(21):12012-21. PubMed ID: 15479840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
    Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
    Meher BR; Wang Y
    J Phys Chem B; 2012 Feb; 116(6):1884-900. PubMed ID: 22239286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.
    Yu Y; Wang J; Shao Q; Shi J; Zhu W
    Sci Rep; 2015 May; 5():10517. PubMed ID: 26012849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
    Koh Y; Nakata H; Maeda K; Ogata H; Bilcer G; Devasamudram T; Kincaid JF; Boross P; Wang YF; Tie Y; Volarath P; Gaddis L; Harrison RW; Weber IT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3123-9. PubMed ID: 14506019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor.
    Nivesanond K; Peeters A; Lamoen D; Van Alsenoy C
    J Chem Inf Model; 2008 Jan; 48(1):99-108. PubMed ID: 18173253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
    Surleraux DL; Tahri A; Verschueren WG; Pille GM; de Kock HA; Jonckers TH; Peeters A; De Meyer S; Azijn H; Pauwels R; de Bethune MP; King NM; Prabu-Jeyabalan M; Schiffer CA; Wigerinck PB
    J Med Chem; 2005 Mar; 48(6):1813-22. PubMed ID: 15771427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
    Meher BR; Wang Y
    J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
    Yedidi RS; Garimella H; Aoki M; Aoki-Ogata H; Desai DV; Chang SB; Davis DA; Fyvie WS; Kaufman JD; Smith DW; Das D; Wingfield PT; Maeda K; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3679-88. PubMed ID: 24752271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
    Dierynck I; De Wit M; Gustin E; Keuleers I; Vandersmissen J; Hallenberger S; Hertogs K
    J Virol; 2007 Dec; 81(24):13845-51. PubMed ID: 17928344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.
    Kovalevsky AY; Liu F; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
    J Mol Biol; 2006 Oct; 363(1):161-73. PubMed ID: 16962136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
    Shen CH; Wang YF; Kovalevsky AY; Harrison RW; Weber IT
    FEBS J; 2010 Sep; 277(18):3699-714. PubMed ID: 20695887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.
    Tie Y; Boross PI; Wang YF; Gaddis L; Hussain AK; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
    J Mol Biol; 2004 Apr; 338(2):341-52. PubMed ID: 15066436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Leonis G; Steinbrecher T; Papadopoulos MG
    J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.
    Kovalevsky AY; Ghosh AK; Weber IT
    J Med Chem; 2008 Oct; 51(20):6599-603. PubMed ID: 18808097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
    Markland W; Rao BG; Parsons JD; Black J; Zuchowski L; Tisdale M; Tung R
    J Virol; 2000 Aug; 74(16):7636-41. PubMed ID: 10906218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.
    Chen J; Liang Z; Wang W; Yi C; Zhang S; Zhang Q
    Sci Rep; 2014 Nov; 4():6872. PubMed ID: 25362963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring molecular mechanism of allosteric inhibitor to relieve drug resistance of multiple mutations in HIV-1 protease by enhanced conformational sampling.
    Chen J; Peng C; Wang J; Zhu W
    Proteins; 2018 Dec; 86(12):1294-1305. PubMed ID: 30260044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
    Hou T; Yu R
    J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.